According to a commentary, these results are clearly impressive, but there are several aspects that need to be interpreted prudently. First, the bortezomib, melphalan, and prednisone (VMP) group received a fixed-duration therapy of nine cycles followed by observation, whereas the daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) group continued daratumumab monotherapy every 4 weeks beyond nine cycles of induction. Second, the trial used a control treatment that is not the standard of care globally. Third, the benefit of overall survival and progression-free survival on the subsequent line of therapy in the D-VMP group could have been observed because of suboptimal second and subsequent lines of therapy in the VMP group. Finally, there appeared to be a modest improvement in overall survival for patients with high cytogenetic risk in the D-VMP group compared with patients with standard cytogenetic risk; perhaps the advantage would emerge with further follow-up. The percentage of patients with multiple myeloma who had a high-risk cytogenetic profile in ALCYONE was relatively small; therefore, it is challenging to draw concrete conclusions.